The 20th annual Rice Business Plan Competition took place virtually from June 17 to 19 and awarded over $1.2 million in investment and cash prizes. Photo courtesy of Rice University

For the 20th year, the Rice Business Plan Competition has awarded prizes and investments to student-led startups from around the ward. While this year's competition was postponed and virtually held, the show went on with 42 startups pitching virtually June 17 to 19.

After whittling down the 42 startups to seven finalists, the RBPC judges named the winners. And, this year, all seven finalists walked away with a monetary prize. Here's how the finalists cleaned up.

  • Aurign, which provides publishing services for recording artists and record labels, from Georgia State University, won first place and the $350,000 grand prize from GOOSE Capital. Aurign also won RG Advisory Partners' prize of $25,000, bringing the company's total to $375,000 won.
  • Coming in second place with a $100,000 investment prize (awarded by Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce) was Dartmouth College's nanopathdx, which is creating diagnostic tools for chronic and infectious diseases. Nanopathdx won two other monetary prizes — the $25,000 Spirit of Entrepreneurship Prize from Pearland Economic Development and Ncourage's $25,000 award focused on female entrepreneurs — for a total of $150,000 won. The company also won the Palo Alto Software Live Plan award and an award from SheSpace.
  • Harvard University's Fractal — a cloud computing tech company that enables powerful remote work tools — won third place and a $50,000 investment from Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce. The company also won an $100,000 investment from the Houston Angel Network, bringing their total prize to $150,000.
  • In fourth place was RefresherBoxx from RWTH Aachen University in Germany. The company has created disinfecting devices for clothing and recently pivoted to create a COVID-19 application. The startup won a $5,000 prize sponsored by Norton Rose Fulbright for placing in the finals, but also walked away with a $100,000 investment from TiE Houston Angels, bringing the startup's total prize money to $105,000.
  • The University of Chicago's Beltech, which has created a safer, longer lasting battery, won fifth place and a $5,000 award sponsored by EY. The company also won an $100,000 investment from the Houston Angel Network, bringing the total amount won to to $105,000.
  • Cardiosense from Northwestern University, which has created a wearable heart monitor device, took sixth place in the competition and won a $5,000 award sponsored by Chevron Technology Ventures. Cardiosense also won two other monetary prizes — TMC Innovation's $100K TMC Healthcare Innovation investment and NASA's $25,000 Human Health and Performance Award — bringing the total amount won to $130,000. The company also won OFW Law's prize.
  • Relavo, a safer home dialysis treatment company from Johns Hopkins University, came in seventh place and won a $5,000 prize sponsored by Shell Ventures. Relavo also won three other monetary prizes — the $25,000 Pediatric Device Prize from the Southwest National Pediatric Device Consortium, Ncourage's $25,000 award focused on female entrepreneurs, and Polsinelli's $15,000 technology prize — bringing the startup's total prize money to $70,000.
Some of the competition's participating startups outside of the seven finalists won monetary prizes. Here's a list of those.
  • BIOMILQ, a female-founded startup out of Duke University that can cultivate breast milk outside of the body, won The Artemis Fund's $100,000 prize.
  • The University of Maryland's Algen Air — a natural air purifier that uses algae to filter air — won NASA's $25,000 Space Exploration Award.
  • SlumberFlow — a sleep apnea treatment device from the University of Michigan — won the the $25,000 Pediatric Device Prize from the Southwest National Pediatric Device Consortium.
  • Rice University's own EVA, which streamlines vascular access for medical professionals, won the Texas Business Hall of Fame's $25,000 prize.
  • Contraire — a predictive analysis control system for aeration process within municipal wastewater treatment plants — from Oklahoma State University won Polsinelli's $15,000 Energy Innovation prize.
While not ready to name investment recipients at the virtual event, the Owl Investment Group announced they will be inviting some companies to pitch to them directly.
Additional non-monetary prizes included:
  • Capital Factory's Golden Ticket prize to EVA from Rice University, NanoCare from Texas State University, and SeebeckCell Technologies from the University of Texas at Arlington.
  • Mercury Fund's Elevator Pitch winners included: KnoNap from Georgetown University (first place), Steeroflex from the University of California San Diego (second place), Encapsulate from the University of Connecticut (third place), RefresherBoxx (fourth place), and NanoCare from Texas State University (fifth place).
The virtual event wrapped up with the announcement of the 21st annual RBPC, which is set for April 8 to 10 next year.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”